Tag : Takeda

Latest News

Takeda réaffirme son engagement de longue date pour faire progresser les traitements des troubles hémorragiques rares grâce à des études mettant en évidence des données probantes du monde réel et la thérapie génique de recherche lors de l’ASH 2019

Newsemia
OSAKA, Japon–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), a présenté aujourd’hui neuf affiches portant sur des données hématologiques dans le cadre du 61e Congrès...
Latest News

Takeda va présenter les résultats de son essai de Phase 3, TOURMALINE-AL1, portant sur le NINLARO pour le traitement des patients atteints d’amyloïdose

Newsemia
CAMBRIDGE, Massachusetts, & OSAKA, Japon–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) a annoncé aujourd’hui que les résultats de l’essai TOURMALINE-AL1 seront présentés au cours d’une séance...
Latest News

Takeda presenterà i risultati dello studio clinico di fase 3 TOURMALINE-AL1 su NINLARO in pazienti affetti da amiloidosi

Newsemia
CAMBRIDGE, Massachusetts e OSAKA, Giappone–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) oggi ha annunciato che i risultati dello studio clinico TOURMALINE-AL1 saranno presentati durante una sessione...
Latest News

Samenvatting: Takeda presenteert langetermijngegevens in ALK + NSCLC met ALUNBRIG® (brigatinib) blijft superioriteit in de eerstelijn aantonen na twee jaar follow-up

Newsemia
CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) heeft vandaag bijgewerkte gegevens bekendgemaakt van de Fase 3 ALTA-1L-studie, die...
Latest News

Takeda presenta los datos de largo plazo de ALUNBRIG (brigatinib) en ALK+ NSCLC ® que continúan demostrando la superioridad en la primera línea después de dos años de seguimiento

Newsemia
CAMBRIDGE, Massachusetts y OSAKA, Japón–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) anunció hoy los datos actualizados del estudio de fase 3 ALTA-1L, que evaluó a ALUNBRIG...
Latest News

Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up

Newsemia
CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib...
Latest News

Takeda Apresenta Dados de 18 Meses do Teste Principal da Fase 3 do Candidato à Vacina contra Dengue à Sociedade Americana de Medicina Tropical e Higiene (ASTMH) no 68o Encontro Anual

Newsemia
CAMBRIDGE, Mass. & OSAKA, Japão–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502 / NYSE:TAK) (“Takeda”) anunciou hoje que os resultados do teste da fase principal 3 em...
Latest News

Riassunto: Takeda presenta i dati di 18 mesi dallo studio clinico pivotale di fase III sul candidato vaccino anti-dengue in occasione del 68o Congresso annuale della American Society of Tropical Medicine and Hygiene (ASTMH)

Newsemia
CAMBRIDGE, Massachusetts e OSAKA, Giappone–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502 / NYSE:TAK) (“Takeda”) oggi ha annunciato che i risultati aggiornati dallo studio pivotale di fase...
Latest News

Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting

Newsemia
CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine...
Latest News

Riassunto: Takeda presenta i dati a lungo termine relativi a ALK+ NSCLC che mostrano come ALUNBRIG® (brigatinib) continui a dimostrare superiorità nella prima linea dopo due anni di follow-up

Newsemia
CAMBRIDGE, Massachusetts e OSAKA, Giappone–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) oggi ha annunciato dati aggiornati dalla Fase 3 della sperimentazione clinica ALTA-1L, nel corso della...
Latest News

Takeda Destacará Portfólio Ampliado de Produtos em Oncologia e Hematologia no 61º Encontro Anual da Sociedade Americana de Hematologia (ASH)

Newsemia
CAMBRIDGE, Mass. & OSAKA, Japão–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) anunciou hoje que apresentará um total de 29 resumos patrocinados pela empresa no 61o...
Latest News

Takeda meldet starke Ergebnisse für das zweite Quartal des Geschäftsjahres 2019 und hebt die Gewinnprognose für das Gesamtjahr an

Newsemia
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TOKYO: 4502) (NYSE: TAK): Der zugrunde liegende Umsatz sank um -0,2 Prozent gegenüber dem Pro-forma-Umsatz aus dem Geschäftsjahres 2018 H12 Die 14...
Latest News

Takeda divulga resultados sólidos do segundo trimestre do ano fiscal de 2019 e publica orientação de lucro para o ano inteiro

Newsemia
OSAKA, Japão–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): A receita subjacente reduziu -0,2% em comparação com a receita pro forma do primeiro semestre do ano fiscal...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy